共 83 条
[1]
Cromer D(2021)Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Nat Rev Immunol 21 395-404
[2]
Juno JA(2022)Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 N Engl J Med 386 2201-2212
[3]
Khoury D(2022)Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study The Lancet Rheumatology 4 e338-e350
[4]
Goldberg Y(2021)Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab Gut 70 865-875
[5]
Mandel M(2021)Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC) Mult Scler Relat Disord 55 880-882
[6]
Bar-On YM(2021)SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort JAMA Neurol 78 102580-1935
[7]
Wieske L(2022)DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study Semin Arthritis Rheum 55 1928-e29
[8]
van Dam KPJ(2022)SARS-CoV-2 triggering autoimmune diseases Cytokine 154 e417-3499
[9]
Steenhuis M(2021)A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center J Autoimmun 117 e77969-397
[10]
Kennedy NA(2022)Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients Rheumatology (Oxford) 61 100-1230